Pyxis Oncology (PYXS) Income from Continuing Operations: 2024-2025
Historic Income from Continuing Operations for Pyxis Oncology (PYXS) over the last 2 years, with Sep 2025 value amounting to -$22.0 million.
- Pyxis Oncology's Income from Continuing Operations fell 3.77% to -$22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.4 million, marking a year-over-year change of. This contributed to the annual value of -$77.3 million for FY2024, which is 4.66% down from last year.
- Latest data reveals that Pyxis Oncology reported Income from Continuing Operations of -$22.0 million as of Q3 2025, which was down 3.99% from -$21.2 million recorded in Q2 2025.
- In the past 5 years, Pyxis Oncology's Income from Continuing Operations registered a high of -$3.3 million during Q2 2024, and its lowest value of -$35.6 million during Q4 2024.
- Its 2-year average for Income from Continuing Operations is -$18.4 million, with a median of -$21.2 million in 2024.
- Data for Pyxis Oncology's Income from Continuing Operations shows a maximum YoY slumped of 549.82% (in 2025) over the last 5 years.
- Quarterly analysis of 2 years shows Pyxis Oncology's Income from Continuing Operations stood at -$35.6 million in 2024, then fell by 3.77% to -$22.0 million in 2025.
- Its last three reported values are -$22.0 million in Q3 2025, -$21.2 million for Q2 2025, and -$21.7 million during Q1 2025.